Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 10:40PM GMT
Release Date Price: $16.28 (-1.81%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Welcome to the afternoon session of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And this afternoon, we have Travere Therapeutics with us. Representing Travere is Eric Dube, President and CEO; and Peter Heerma, Chief Commercial Officer. Eric is going to start off with a few preparing remarks and then we'll jump into Q&A.

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Great. Well, thank you, Greg, and Bank of America for hosting us. This is an incredibly exciting year for Travere. We have been working on both continuing our commercial presence as well as preparing for what has been early signs of success with approval of FILSPARI in IgA nephropathy as well as completion of several Phase III programs within our pipeline, two of which are with sparsentan, both in FSGS and IgA nephropathy as well as the potential initiation of a Phase III with our pegtibatinase asset later this year in classical homocystinuria

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot